In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

Novo Nordisk accounts for 34% of the global diabetes ... fatty liver disease, sleep apnea, and Alzheimer's, and Novo and Lilly are running phase 3 trials of semaglutide and tirzepatide in many ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk ... the risk of Alzheimer’s disease and substance ...

Perhaps the best example here is Alzheimer's disease, a worsening problem considering the world's aging population, but one where there are few approved medicines. Further, Novo Nordisk has other ...